Inovio Historical Cash Flow
| INO Stock | USD 1.73 0.03 1.70% |
Analysis of Inovio Pharmaceuticals cash flow over time is an excellent tool to project Inovio Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 13.6 M or Other Cashflows From Financing Activities of 17.9 M as it is a great indicator of Inovio Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Inovio Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Inovio Pharmaceuticals is a good buy for the upcoming year.
Inovio |
About Inovio Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Inovio balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Inovio's non-liquid assets can be easily converted into cash.
Inovio Pharmaceuticals Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Inovio Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Inovio Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Inovio Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Inovio Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.At this time, Inovio Pharmaceuticals' Dividends Paid is very stable compared to the past year. As of the 30th of March 2025, Investments is likely to grow to about 109.3 M, while Change To Inventory is likely to drop about 13.3 M.
| 2024 | 2025 (projected) | Issuance Of Capital Stock | 36.0M | 34.2M | Net Borrowings | 154.5K | 146.7K |
Inovio Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Inovio Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Inovio Pharmaceuticals cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (963.9K) | 935.8K | (55.2M) | 15.5M | 14.0M | 13.3M | |
| Change In Cash | 228.5M | (179.6M) | (24.8M) | (32.0M) | 51.5M | 54.1M | |
| Free Cash Flow | (179.5M) | (216.9M) | (217.2M) | (124.7M) | (104.1B) | (98.9B) | |
| Change In Working Capital | (71.1M) | 50.4M | 19.8M | (10.3M) | (2.7M) | (2.5M) | |
| Begin Period Cash Flow | 22.2M | 250.7M | 71.1M | 46.3M | 14.3M | 13.6M | |
| Other Cashflows From Financing Activities | 10.6M | 2.1M | (1.1M) | (466.6K) | 31.9M | 17.9M | |
| Depreciation | 4.6M | 4.7M | 5.5M | 3.5M | 3.1M | 2.4M | |
| Other Non Cash Items | 2.4M | 858.6K | 11.7M | 6.5M | 3.2B | 3.3B | |
| Capital Expenditures | 1.5M | 1.2M | 969.2K | 320.9K | 487.8K | 463.4K | |
| Total Cash From Operating Activities | (178.0M) | (215.7M) | (216.2M) | (124.4M) | (104.1B) | (98.9B) | |
| Net Income | (167.5M) | (303.7M) | (279.8M) | (135.1M) | (107.3B) | (101.9B) | |
| Total Cash From Financing Activities | 465.3M | 211.5M | 81.8M | 5.0M | 51.5M | 58.6M | |
| End Period Cash Flow | 250.7M | 71.1M | 46.3M | 14.3M | 65.8M | 34.5M | |
| Change To Liabilities | (4.6M) | 3.3M | 26.1M | 32.6M | 37.5M | 39.4M | |
| Stock Based Compensation | 15.6M | 26.3M | 22.6M | 11.1M | 6.6M | 6.3M | |
| Change To Account Receivables | (17.0M) | 11.0M | (3.7M) | 9.3M | 1.2M | 1.3M | |
| Sale Purchase Of Stock | (892.9K) | (4.0M) | (4.6M) | (1.4M) | (1.3M) | (1.2M) | |
| Total Cashflows From Investing Activities | (9.0M) | (58.8M) | (175.3M) | 109.6M | 98.6M | 103.6M | |
| Investments | (93.2M) | (174.1M) | 112.6M | 121.4M | 104.1M | 109.3M | |
| Change Receivables | 2.0M | (17.0M) | 11.0M | (3.7M) | (4.3M) | (4.0M) | |
| Cash And Cash Equivalents Changes | (1.5M) | 228.5M | (179.6M) | (24.8M) | (22.3M) | (21.2M) | |
| Cash Flows Other Operating | 3.2M | (96.3M) | 18.2M | 1.9M | 1.7M | 1.8M | |
| Other Cashflows From Investing Activities | (2.8M) | (1.4T) | 110.6M | 6.2M | (2.3B) | (2.5B) | |
| Change To Netincome | 17.4M | 95.9M | 27.5M | 30.0M | 34.5M | 20.1M | |
| Change To Operating Activities | (3.5M) | (57.9M) | 16.2M | (6.9M) | (6.3M) | (6.6M) | |
| Issuance Of Capital Stock | 454.5M | 209.4M | 83.0M | 10.3M | 36.0M | 34.2M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.95) | Revenue Per Share | Quarterly Revenue Growth 0.14 | Return On Assets | Return On Equity |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.